Get started
Johnson & Johnson 6.95 % Debs 1999-1.9.29 Cert Deposito Arg Repr 1 DebsJohnson & Johnson 6.95 % Debs 1999-1.9.29 Cert Deposito Arg Repr 1 DebsJohnson & Johnson 6.95 % Debs 1999-1.9.29 Cert Deposito Arg Repr 1 Debs

Johnson & Johnson 6.95 % Debs 1999-1.9.29 Cert Deposito Arg Repr 1 Debs

No trades
See on Supercharts
OverviewNewsIdeasMindsTechnicalsSeasonalsBonds

Trade ideas

JNJ - Time To Lock In ProfitIs printing a shakeout that completes a double stab up slightly higher high (liquidity sweep) And now a bearish impulsive candle is printing. JNJ has been very strong, but I think this signals that one way or another there will be another wave down in the pipeline. I'll be looking to pick this one back up later - perhaps. This analysis is shared for educational purposes only and does not constitute financial advice. Please conduct your own research before making any trading decisions.
NYSE:JNJShort
by dRends35
JOHNSON & JOHNSON Short-term correction ahead.Johnson & Johnson (JNJ) has been trading within a 5-month Channel Up since the June 20 Low, with the 1D MA50 (red trend-line) in firm Support. The 4H RSI is printing a peak formation similar to all previous Higher Highs of the pattern. What followed after all those tops were pull-backs just under the 0.382 Fibonacci retracement level but never below the 1D MA50. As a result, we expect a technical pull-back (Bearish Leg) on this stock to $197.50. --- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** --- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot
JNJ Price Target Summary (This Week) Johnson & Johnson (JNJ) is currently trading around $204. Analyst consensus price targets for the next 12 months are mostly in the $200–$207 range, with the highest targets around $230, but these are long-term estimates — not short-term. A move to $228 this week is unlikely, as JNJ is a large, stable stock and there is no major catalyst expected that could push the price up ~12% in a few days. In the short term, JNJ is more likely to trade sideways or see modest gains, unless unexpected positive news or strong sector momentum appears
NYSE:JNJ
by rzv09190
1
"On the 1 hour timeframe i looked for a candlestick pattern"I missed this entry on this stock NYSE:JNJ but atleast i got to see the entry. This entry happen, On the 1 hour timeframe i looked for a candlestick pattern to show me the bottom reversal After seeing the candlestick in this case the bullish engulfing Showed me the bottom reversal then Boom the MCAD turned the MACD is the safety net showing you the confirmation on the buying chart especially on the 1 hour chart -- Trade Insight: This represents a maximum probability bullish continuation setup because: • All timeframes show maximum bullish momentum (Dark Green MACD) • Daily shows the strongest bullish pattern (Rising 3 Soldiers) • 4H & 1H confirm with Bullish Separating Lines (sustained buying pressure) • Perfect storm of continuation signals across all timeframes Rocket boost this content to learn more Disclaimer: Trading is risky please use a simulation trading account before you trade with real money
NYSE:JNJLong
by lubosi
Johnson & Johnson (JNJ) Finds Support at Key Level Johnson & Johnson (JNJ) continues to demonstrate strong defensive positioning and renewed momentum as structural shifts in its business and improving sentiment fuel a breakout from a multiyear downtrend. After the successful separation of its consumer health arm, J&J is now more focused on its pharmaceutical and medical technology segments—two higher-margin businesses with long-term growth drivers tied to immunology, oncology, surgical robotics and med-tech innovation. Fundamentally, J&J’s pharma portfolio remains robust, supported by key drugs such as Darzalex, Stelara and Tremfya, with new pipeline readouts expected to broaden the company’s long-term revenue base. Meanwhile, the med-tech division continues to recover as global elective procedures normalize, giving J&J steady top-line expansion despite macro uncertainty. Another important shift is the decreasing overhang from litigation issues—particularly talc claims—which has weighed on the stock for years. As settlements progress and legal clarity improves, investor confidence is returning, contributing to the stock’s recent momentum surge. Additionally, J&J maintains one of the strongest balance sheets in the healthcare sector, with consistent cash flow generation supporting dividends and R&D investment. Technical Outlook The chart shows JNJ breaking strongly above a long-term descending channel that has contained price action since 2022. This breakout, accompanied by rising volume, signals a major trend reversal from a multiyear downtrend to a new bullish phase. Price has also reclaimed a key horizontal level around $185, turning previous resistance into new support. The current momentum suggests JNJ may now target the next major resistance zone near $205–210 phychological high. The RSI remains elevated but healthy, reflecting strong bullish buying without extreme overextension. As long as JNJ holds above the $185 support region, the bullish structure remains intact. Overall, Johnson & Johnson approaches 2026 with improving fundamentals, fading legal risks and a clean technical breakout, creating a constructive setup for continued upside.
NYSE:JNJLong
by DEXWireNews
Johnson & Johnson Wave Analysis – 14 November 2025- Johnson & Johnson broke pivotal resistance level 194.00 - Likely to rise to resistance level 200.00 Johnson & Johnson recently broke above the pivotal resistance level 194.00, which stopped the previous impulse wave (3) in the middle of October. The breakout of the resistance level 194.00 accelerated the active impulse wave 3 – which belongs to the intermediate impulse wave (5) from the end of October. Given the strong daily uptrend, Johnson & Johnson can be expected to rise to the next round resistance level 200.00 (target for the completion of wave 3).
NYSE:JNJLong
by FxPro
Johnson & Johnson: Extended Wave 3 Nearing Completion, Watching Johnson & Johnson is showing a very nice recovery with clear impulsive price action since breaking out of the downward channel back in July. The structure suggests an ongoing trend with an extended black wave three that now has five waves up as expected, after a nice fourth wave retracement to 186 in last few weeks. So if we are correct then market is now in late stage of an extended wave 3 which could be coming to an end somewhere around 200 level; near the channel resistance. That said, be aware of a new higher degree reversal going into end of this year. However, once we see next retracement, interesting support can once again be at 186-180 region. Highlights: Trend: Bullish (fifth wave within ongoing wave three) Support: 186,180 Resistance: 200–208 Invalidation: 169 Note: Favoring continuation higher after a pullback toward support
NYSE:JNJ
by ew-forecast
Bear Call Spread on JNJBear Call Spread Sell 195 Call strike and Buy 200 Call Strike, Exp: Nov 28 (45 DTE) for no less than $1.55 Trade has about 67% probability of profit Taking advantage of high IV rank of 40 Credit received = $155 BP Effect = $345 Max Loss = (5 - 1.55) * 100 = $345 Breakeven = 195 + 1.55 = $196.55 Percentage return: (155 / 345) * 100 =44.928% Exit Target: 40% - 70% of Credit received ($62 - $108.50) Stop-loss: close if price threatens the short strike and cost to buy back exceeds 50% of max loss or predefined dollar loss, Exit no later than 7 days before expiration JNJ has seen a significant rise and it at ATH, RSI indicator also shows JNJ being overbought Trade is just for educational purposes and willing to learn consistent option trading
NYSE:JNJ
by Hustle_251_Days
2
Johnson & Johnson. Clean. Soft. Gentle. Growth.Johnson & Johnson (JNJ) stands out as a bellwether in the global healthcare sector, and its nearly 18% stock performance in 2025 reflects both robust fundamentals and compelling technical trends. Fundamental Perspective JNJ maintains a solid financial foundation, underpinned by consistently strong profitability, a diversified business model, and effective capital allocation. As of August 2025, JNJ reported trailing twelve-month (TTM) revenue of $90.6 billion and earnings of $22.7 billion, resulting in a net profit margin of 25% and a gross margin close to 68%. Key profitability metrics such as a Return on Assets (ROA) of 11.7%, Return on Equity (ROE) of 28.9%, and Return on Invested Capital (ROIC) of 13.6% underscore the company's operational efficiency relative to peers in the pharmaceutical industry. From a financial health perspective, JNJ maintains moderate leverage, with a debt/equity ratio of 0.61 and an Altman-Z score of 4.17, signifying financial stability and a low risk of distress. The forward price/earnings (P/E) ratio is 14.9, suggesting that the stock is not particularly expensive for its sector, while the dividend yield remains attractive at 3.16%, appealing to income-oriented investors. The company’s free cash flow yield and high profit quality further enhance its fundamental appeal. JNJ's growth narrative is fueled primarily by its Innovative Medicine and MedTech segments. Drugs like Darzalex and Tremfya continue to deliver high single- to double-digit year-over-year growth, and the MedTech segment is experiencing margin expansion due to scale and product mix improvements. Strategic acquisitions (notably Intra-Cellular Therapies), new regulatory approvals, and a deep late-stage pipeline (over 40 programs) provide resilience and new growth avenues, offsetting pressures from biosimilar competition, patent expirations, and legal settlements. Technical Perspective On the technical side, JNJ’s stock has demonstrated significant momentum. The price reached an all-time 52-week high above $170 per share in early August 2025, following Q2 earnings that exceeded expectations and prompted a nearly 6% surge in share price. Technical indicators are largely positive, with the stock trading above its 50-day and 200-day simple moving averages ($157.43 and $155.56, respectively), reflecting a prevailing bullish trend. The 14-day Relative Strength Index (RSI) stands at 55.85—neither overbought nor oversold—implying stable investor sentiment. Analyst price targets average $173, reflecting modest but continued upside. A key technical resistance zone had developed around $167, which NYSE:JNJ has recently breached. The consensus among technical analysts is the potential for a substantial upward move towards $194 if the breakout holds, while support remains strong at around $140—historically a level where dip buyers emerge. Market sentiment remains bullish, with the Fear & Greed Index indicating broader market caution, while JNJ’s own technical indicators show "Strong Buy". In long-term, JNJ has been supported earlier in 2025 by 10-year SMA, above which stocks are moving since 1980s, i.e. for the past 45 years (on end of year basis). In mid-term, the main technical graph indicates on major 5-year old bearish trend reversal. Reasons for Recent Growth JNJ’s recent growth is attributed to several convergent factors: Strong Q2 2025 earnings performance, leading management to raise full-year revenue and EPS guidance above analysts’ expectations. Continued strength in key growth drivers: new drug launches in oncology and immunology, robust MedTech expansion, and improved operating margins. Favorable foreign exchange and a reduction in tariff costs, redirecting capital to R&D. Positive pipeline developments and strategic acquisitions. Successful navigation of legal risks and clarity regarding settlements (including talc litigation), which have reduced major uncertainties. Broad overall market resilience and a rotation toward defensive healthcare shares. In summary, Johnson & Johnson’s combination of strong and diversified fundamentals, attractive income profile, and bullish technical signals—amplified by improved guidance and innovation momentum—help explain the stock’s recent appreciation and continued investor confidence. -- Best wishes, @PandorraResearch Team
NYSE:JNJ
by PandorraResearch
JNJ Undervalued with Strong Fundamentals Pharma Giant?JNJ – Financial Performance & SWOT Analysis JNJ Undervalued with Strong Fundamentals Pharma Giant? (1/9) Good morning, folks! JNJ is steady 📈, at $ 191.08 up 35.31% YTD per October 10, 2025. Q2 revenue shakes up this pharma play , let’s dive in! 📊🔥 Tag a friend who needs this investing hack! (2/9) – PRICE PERFORMANCE • Last week: $ 191.08, up from $ 189.69 close 📈 • YTD 2025: up 35.31%, outpacing S&P 500 🔄 • Q2 2025: revenue up to $23.74B 🚀 This pharma stock’s volatility, earnings beats pop! 💥 (3/9) – MARKET POSITION • Market Cap: $ 460.19B, industry leader 🏆 • Avg Volume: 8.67M shares, high liquidity 💧 • Trend: P/E 19.1x below fair ratio 👑 This asset’s dominance, holding tight! 🔒 (4/9) – KEY DEVELOPMENTS • Q2 earnings: revenue $23.74B, EPS $2.77 beat 💰 • Price target: Goldman Sachs to $212 🏭 • Sentiment: undervalued on valuation models 📈 This pharma move, stable push! ⚡ (5/9) – RISKS IN FOCUS • Regulations: pharma sector impacts ⚠️ • Competition: rising from peers 🆚 • Volatility: beta 0.39 swings 📉 This ticker’s exposure, watch these twists! ⚠️🔄 (6/9) – SWOT: STRENGTHS • Earnings stability (consistent.): value driver 🌟 • Diversified portfolio (healthcare.): resilience 🤖 • Dividend yield (strong.): investor appeal 👥 This asset’s edge, built tough! 💪 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: litigation risks, P/E adjustments ⚖️ • Opportunities: growth in medtech, undervaluation 🌍 Can this ticker beat the odds? 🎲 Reply with your take! (8/9) – POLL TIME! JNJ’s $ 191.08 value, your vibe? • Bullish: $210+ soon, earnings beats 📈🚀 • Neutral: Steady, risks balanced ⚖️🛡️ • Bearish: $180 looms, regulation hits 📉⚠️ Chime in below! 💬 Tag a friend for this poll! (9/9) – FINAL TAKEAWAY JNJ’s $ 191.08 stance shows resilience 💪, fundamentals fuel it ⚡. Risks bite 🦈, yet dips are DCA gold 💎. We grab ‘em low, climb like pros! Gem or bust? not advice, just our spin! #JNJ #Investing #Markets #Trading #Finance #ETF #Commodities #DCA #Trends JNJ is potentially undervalued as of October 10, 2025, at $ 191.08, up 35.31% YTD per TradingView. Q2 revenue shapes its path in the pharma space. Here’s a factual financial and strategic breakdown. **Financial Performance** Price Movement: YTD at $ 191.08, up 35.31%. Broader period shows gains amid market rally. Q2 adds upside, with revenue $23.74B. Volume & Market Cap: Avg volume 8.67M shares. Market cap at $ 460.19B. Key Metric: Trailing P/E 20.46, forward P/E 16.42. **SWOT Analysis** Strengths: - Diversified healthcare portfolio. - Strong earnings and dividend yield. - Market leadership in pharma. Weaknesses: - Litigation and regulatory risks. - P/E adjustments for value. - Exposure to economic cycles. Opportunities: - Growth in medtech and pharma. - Undervaluation per models. - Upcoming earnings potential. Threats: - Intense competition. - Market corrections. - Supply chain issues. **JNJ vs. SPY: Key Comparisons** | Aspect | JNJ | SPY | |--------|------|-----| | Purpose & Scope | Pharma and healthcare focus | Broad market index tracking | | Dynamics | Beta 0.39 volatility vs. lower 1.00 | Steady benchmark | | Market Position | Up 35.31% YTD, undervalued P/E vs. S&P gains | Stable exposure | **Investor Considerations: DCA** Dollar Cost Averaging: JNJ’s volatility suits dip-buying. At $ 191.08, $10,000 buys ~52 shares; a 10% dip to $ 172 nets ~58 shares. **Outlook & Risks** JNJ’s $ 191.08 position shows stable edge, with revenue growth. Regulations loom, yet dip grabs turn volatility into gains. Growth or dividends could sway it, but time’s our edge. Gem or fade? Depends on healthcare demand.
NYSE:JNJ
by DCAChampion
JNJ is unchainedJNJ is unchained JNJ has spent 4 years moving sideways, which basically means the market agreed this was the fair price f or the stock. But this August, we saw analysts like Joanne Wuensch from Citi start pointing to the $200 zone , and it looks like she might have been right. 🚀 If you missed the rectangle breakout, JNJ is now giving a second amazing opportunity . After a strong rally and a confirmed breakout ending the balance between bulls and bears, we’re now in a bull flag. Traders are taking profits, but it’s clear that sellers can’t take control. Volume keeps dropping, and that usually sets up for an upside breakout soon. This looks like a very attractive buy with potential toward $190–$200 in just a few days, with a tight stop-loss of around 1%. 🟢 For more ideas, follow or subscribe to the newsletter.
NYSE:JNJLong
by TopChartPatterns
4
Johnson & Johnson Bulls Break the FlagJohnson & Johnson has been in a strong uptrend, with buyers consistently driving price higher. After the impulsive rally, price consolidated into a downward-sloping flag, where sellers tried to take control but failed to push lower. Buyers then stepped back in, breaking out of the flag with strength. That’s our long entry signal, confirming buyers are firmly in control and positioning for continuation toward the next target around 190. The fundamentals for J&J are mostly supportive: strong earnings, raised guidance, strategic acquisition add weight to bullish bias and the technical outlook. But stay alert to catalysts that could turn sentiment fast.
NYSE:JNJLong
by TrendDiva
18
Band-Aids to Blowouts: Shorting J&J's This short trade is based on the idea that JNJ's stock price has extended beyond a long-term upward channel, suggesting a high-probability mean reversion or correction back toward the established trendline. The chart suggests a bearish divergence or a temporary blow-off top scenario. The price has accelerated sharply, poking above the main channel (orange line). The strategy capitalizes on the expectation that this extended move will fail, leading to a strong retracement to "reset" the stock back into its longer-term average trend. Macro Thesis: The bearish case argues that JNJ's stock price, which has historically commanded a premium for its stability, is vulnerable to a correction as the market fully prices in the combined near-term negative catalysts: the immediate drag from Stelara's LOE, the ongoing financial uncertainty of the talc lawsuits, and the general sector pressure from US drug pricing reform. This confluence of factors makes the stock less of a "safe haven" and more susceptible to the technical correction suggested by your chart. Trade Idea: Initial Short Entry $192.20 (Light Red Arrow) This price sits right at the upper boundary of the short-term rising channel (pink line) and may represent the first sign of exhausted momentum following a sharp run-up. Initiating a light position here hedges against a potential immediate drop. Add to Short $198.11 (Dark Red Arrow) This price is at or near the upper boundary of the long-term channel (orange line). This level is the key resistance for the entire price structure. If the price reaches here and fails to break out convincingly, it's a strong signal of a major rejection and provides a high-confidence level to increase the short position size. Target Exit (Take Profit) $172.07 (Green Arrow) This target is set near the midpoint of the current rising channel (dark red line). This level represents a high-probability support zone and the natural point for the stock to revert to after correcting from an overbought or extended state. This offers a potential return of 10.5% to 13.4% from the two entry points. Disclaimer: This analysis is based solely on the technical indicators and levels presented in the provided image and is not financial advice. The stock market is inherently unpredictable, and you should always conduct your own research before making investment decisions.
NYSE:JNJShort
by GoldenTraderz_2025
Johnson & Johnson Wave Analysis – 30 September 2025 - Johnson & Johnson broke key resistance level 180.00 - Likely to rise to resistance level 190.00 Johnson & Johnson recently broke sharply above the key resistance level 180.00 (which stopped the previous minor impulse wave 3 at the end of August). The breakout of the resistance level 180.00 accelerated the active impulse wave 5 of the intermediate impulse wave (3) from April. Given the predominant daily uptrend, Johnson & Johnson can be expected to rise to the next resistance level 190.00, target price for the completion of the active impulse wave 5.
NYSE:JNJLong
by FxPro
JNJ Pre-Market Write Up (Sept 12)JNJ sitting right under resistance with a fat wall of dark pool prints stacked in the 179–180 zone. CPI is gonna decide if this rips or rejects. 📈 Calls: If price breaks 179.79 and holds, I’m looking long. First TP 180.08, stretch TP 181.10. That’s where the next dark pool cluster sits, so I’m scaling out there. 📉 Puts: If we reject 179.78, then it’s puts. TP1 178.98, TP2 178.57. Heavy liquidity around those levels, so I’m taking profits as we test them. The tape is loaded with dark pool activity around $175–$180, so expect chop. Don’t marry bias, let price show direction.
NYSE:JNJ
by davekclinton76
Johnson & Johnson Wave Analysis – 11 September 2025- Johnson & Johnson reversed from the support area - Likely to rise to next resistance level 180.8 Johnson & Johnson recently reversed from the support area between the pivotal support level 175.00 (which stopped the earlier correction a) and the lower daily Bollinger Band. The upward reversal from this support area created the daily Japanese candlesticks reversal pattern Morning Star Doji. Given the clear daily uptrend, Johnson & Johnson can be expected to rise to the next resistance level 180.8 (former top of wave 3).
NYSE:JNJLong
by FxPro
JNJ | Long Setup | Accumulation Breakout | Sep 2, 2025📌 JNJ | Long Setup | Accumulation Breakout + ROI Horizon Q4 2026 | Sep 2, 2025 🔹 Thesis Summary Johnson & Johnson has broken out of a multi-year accumulation range with a confirmed retest. Despite flat analyst outlooks, the asymmetric reward profile, institutional interest, and macro hedge potential make this a compelling long-hold into late 2026. 🔹 Trade Setup Bias: Long Entry Zone: $173 – $178 Stop Loss: $159.14 (below prior range and hedge zone) Take-Profits: • TP1: $198.75 (70% out) • TP2: $215.69 (85% out) • Max Target: $246.79 (Q4 2026 projection) Risk/Reward: ~1.8R | ROI expected by Oct 2026 🔹 Narrative & Context This setup builds on a classic breakout-retest structure from a prolonged accumulation range (2022–2025), confirmed by price action and volume profile support. The zone from $148–$159 acts as a compound hedge area, while $138 remains historical demand. Catalysts at play: Q2 2025 earnings beat and guidance upgrade Tariff burden halved ($400M → $200M) $14.6B acquisition in neuropsychiatric biotech (Intra‑Cellular Therapies) Politically-linked accumulation noted in April 2025 Although consensus targets show little upside (avg. $173–$178), price action and strategic accumulation suggest the market may be underpricing longer-term growth potential. 🔹 Macro Considerations Seasonality: Sept–Nov tends to underperform across large caps, aligning with the expected ~7% correction back into the compound zone before trend continuation. Valuation: Slightly overvalued, justifying phased entries and hedge levels below $159. Flow Note: Capital rotating out of defensives. However, JNJ’s setup offers long-duration positioning for reentry on broader market risk-off. Correlation Profile (5-Year Historical): S&P 500: +54% Oil (CL): +58% Gold (XAU): +39% This mixed correlation profile enhances its use as a portfolio balancer during macro uncertainty or rotation phases. 🔹 Forward Path A weekly close above $198.75 unlocks upside invalidation of current analyst targets. Should this post gain traction, I’ll provide: Weekly chart structure & dividend-compounding angles Relative strength vs. XLV and peer group (MRK, PFE) Litigation & pipeline risk monitor 🔻 Like & Follow for structured ideas, not signals. I post high-conviction setups here before broader narratives play out. ⚠️ Disclaimer: This is not financial advice. Always do your own research. Charts and visuals may include AI enhancements.
NYSE:JNJLong
by Risk_Adj_Return
2
Do These 4 Steps To Understand A Short Squeeze MindsetYou believe trading the new high is very hard.You have have heard of pump and dump.This is when someone promotes A stock price and "wham!" The stock crashes on you. Maybe you tried using the ADX or DMI indicator and you lost your marbles or mind trying to catch the trend. Yesterday I felt like a total loser because my trading strategy was not working "I understand the Rocket Booster strategy but why is the volatility kicking my butt?" Just like you my indicators stopped working. But there is a solution it's called the short squeeze mindset. Let me tell you how I discovered it. 👉I started thinking using a research tool on trading. 👉I remembered that the best way to measure ranges of price action is using candlesticks patterns So how do you master candlestick patterns? You need to change time-frames In this case I am using the daily time frame. On this timeframe I found a Green bar 🟩 Then I switched to the 4hour time frame and found a red bar 🟥 Thats the short squeeze mindset. So let's list the steps I used so that you can learn to use them as well. 1️⃣The Rocket Booster Strategy 2️⃣The Momentum Trading Style 3️⃣The Short Squeeze Mindset 4️⃣The Stochastic Overbought Zone Combining these 4 steps helped me find the breakout pattern in this stock. Right now do the following: 1️⃣Check the daily chart 2️⃣Do you see the green bar 🟩? 3️⃣Check the 4 hour chart 4️⃣Do you see the red bar 🟥? That's the short squeeze mindset.Its the key to price action entry. You have no excuse if you did the steps above you now see that it is possible to understand the short squeeze mindset. But you need to do this exercise on top before the market opens today.. because this pattern will disappear after the market opens today. So this is your chance to see it. If you are reading this days in the future dont worry. At least you have an idea of what it is.So stayed tuned to these articles for more practical examples. Remember to 🚀 Rocket Boost This Content To Learn More. Disclaimer ⚠️ Trading is risky please learn about risk management and profit taking strategies.Also use a simulation trading account before you use real money.
NYSE:JNJLong
by lubosi